TapewireFind a company

person · Reporting owner

Hansen Gwenn

Disclosed activity across 1 company

Tapewire entity
17989
SEC CIK
0001817160

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Nurix Therapeutics, Inc.NRIX · Entity 1156Chief Scientific OfficerSeptember 01, 2026September 01, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Nurix Therapeutics, Inc.

Report date September 01, 2026 · Filed September 01, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect117,227 Ending reported balance After 2026-09-01 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-09-01 · Exercise / conversion · Acquired 1,452 · Balance 118,679

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Row 2 · 2026-09-01 · Sale · Disposed 1,452 · Balance 117,227

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2029-08-28Direct60,858 Reported balance After 2026-09-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-09-01 · Exercise / conversion · Disposed 1,452 · Balance 60,858

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2: The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2: The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 30, 2023 Filed Nov 1, 2023 20:40 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-23-000058 · wk-form4_1698871229.xml · derivative · entry 5

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
October 30, 2023 Filed Nov 1, 2023 20:40 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,207 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-23-000058 · wk-form4_1698871229.xml · derivative · entry 4

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,861

Underlying: Common Stock · 3,207 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
October 30, 2023 Filed Nov 1, 2023 20:40 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001549595-23-000058 · wk-form4_1698871229.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,162

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 30, 2023 Filed Nov 1, 2023 20:40 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,207 $0.00 $0.00
Disclosure

SEC source: 0001549595-23-000058 · wk-form4_1698871229.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,162

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2023 Filed Aug 1, 2023 20:26 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,884 $9.65 $18,189.45
Disclosure

SEC source: 0001209191-23-043975 · doc4.xml · nonDerivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,955

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $9.61 and the highest price at which shares were sold was $9.82. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
July 30, 2023 Filed Aug 1, 2023 20:26 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-043975 · doc4.xml · derivative · entry 5

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
July 30, 2023 Filed Aug 1, 2023 20:26 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,207 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-043975 · doc4.xml · derivative · entry 4

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,068

Underlying: Common Stock · 3,207 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
July 30, 2023 Filed Aug 1, 2023 20:26 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-043975 · doc4.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,839

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 30, 2023 Filed Aug 1, 2023 20:26 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,207 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-043975 · doc4.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,839

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 01, 2023 Filed May 2, 2023 20:31 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,136 $9.88 $11,219.48
Disclosure

SEC source: 0001209191-23-026515 · doc4.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,632

F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $9.82 and the highest price at which shares were sold was $9.94. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

F1 · balance_after: Includes 1,553 shares of Common Stock acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's employee stock purchase plan.

Read SEC document
April 30, 2023 Filed May 2, 2023 20:31 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,206 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-026515 · doc4.xml · derivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,275

Underlying: Common Stock · 3,206 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
April 30, 2023 Filed May 2, 2023 20:31 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,206 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-026515 · doc4.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,768

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,553 shares of Common Stock acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's employee stock purchase plan.

Read SEC document
February 14, 2023 Filed Feb 15, 2023 21:10 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantRestricted Stock Units · Derivative 24,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-009708 · doc4.xml · derivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement.

F3 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on April 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
February 14, 2023 Filed Feb 15, 2023 21:10 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantEmployee Stock Option (right to buy) · Derivative 88,900 $0.00 Strike: $10.83 $0.00
Disclosure

SEC source: 0001209191-23-009708 · doc4.xml · derivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,900

Underlying: Common Stock · 88,900 shares

Expires 2033-02-13

F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning March 14, 2023 until the option is fully vested on February 14, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
January 30, 2023 Filed Feb 1, 2023 21:15 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,207 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-005904 · doc4.xml · derivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,481

Underlying: Common Stock · 3,207 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
January 30, 2023 Filed Feb 1, 2023 21:15 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,412 $11.78 $16,632.80
Disclosure

SEC source: 0001209191-23-005904 · doc4.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,009

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.60 and the highest price at which shares were sold was $12.00. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
January 30, 2023 Filed Feb 1, 2023 21:15 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,207 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-005904 · doc4.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,421

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 31, 2022 Filed Nov 1, 2022 23:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,165 $12.88 $15,005.78
Disclosure

SEC source: 0001209191-22-055138 · doc4.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,214

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $12.76 and the highest price at which shares were sold was $12.99. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
October 30, 2022 Filed Nov 1, 2022 23:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,207 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-22-055138 · doc4.xml · derivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,688

Underlying: Common Stock · 3,207 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
October 30, 2022 Filed Nov 1, 2022 23:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,207 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-055138 · doc4.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,379

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 09, 2022 Filed Aug 10, 2022 20:15 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantEmployee Stock Option (right to buy) · Derivative 60,298 $0.00 Strike: $18.50 $0.00
Disclosure

SEC source: 0001209191-22-045192 · doc4.xml · derivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,298

Underlying: Common Stock · 60,298 shares

Expires 2032-08-08

F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning September 9, 2022 until the option is fully vested on August 9, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
August 01, 2022 Filed Aug 2, 2022 21:45 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,186 $15.67 $18,584.62
Disclosure

SEC source: 0001209191-22-043961 · doc4.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,172

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $15.32 and the highest price at which shares were sold was $16.01. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
July 30, 2022 Filed Aug 2, 2022 21:45 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,207 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-22-043961 · doc4.xml · derivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,895

Underlying: Common Stock · 3,207 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
July 30, 2022 Filed Aug 2, 2022 21:45 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,207 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-043961 · doc4.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,358

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 02, 2022 Filed May 3, 2022 23:05 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,098 $11.75 $12,901.50
Disclosure

SEC source: 0001209191-22-026892 · doc4.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,151

F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Read SEC document
April 30, 2022 Filed May 3, 2022 23:05 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,206 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-22-026892 · doc4.xml · derivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,102

Underlying: Common Stock · 3,206 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
April 30, 2022 Filed May 3, 2022 23:05 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,206 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-026892 · doc4.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,249

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 846 shares of Common Stock acquired by the Reporting Person on February 15, 2022 pursuant to the Issuer's employee stock purchase plan.

Read SEC document
January 19, 2022 Filed Jan 21, 2022 21:14 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantRestricted Stock Units · Derivative 51,308 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-22-004401 · doc4.xml · derivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,308

Underlying: Common Stock · 51,308 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
January 19, 2022 Filed Jan 21, 2022 21:14 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 GrantEmployee Stock Option (right to buy) · Derivative 115,438 $0.00 Strike: $19.49 $0.00
Disclosure

SEC source: 0001209191-22-004401 · doc4.xml · derivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,438

Underlying: Common Stock · 115,438 shares

Expires 2032-01-18

F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 19, 2022 until the option is fully vested on January 19, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
January 03, 2022 Filed Jan 4, 2022 21:19 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 1,428 $0.00 Strike: $9.57 $0.00
Disclosure

SEC source: 0001209191-22-000730 · doc4.xml · derivative · entry 5

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,905

Underlying: Common Stock · 1,428 shares

Expires 2030-05-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning May 28, 2020 until the option is fully vested on April 28, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

Read SEC document
January 03, 2022 Filed Jan 4, 2022 21:19 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 400 $0.00 Strike: $7.26 $0.00
Disclosure

SEC source: 0001209191-22-000730 · doc4.xml · derivative · entry 4

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,466

Underlying: Common Stock · 400 shares

Expires 2030-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

Read SEC document
January 03, 2022 Filed Jan 4, 2022 21:19 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,828 $28.96 $52,938.88
Disclosure

SEC source: 0001209191-22-000730 · doc4.xml · nonDerivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,197

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
January 03, 2022 Filed Jan 4, 2022 21:19 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 1,428 $9.57 $13,665.96
Disclosure

SEC source: 0001209191-22-000730 · doc4.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,025

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
January 03, 2022 Filed Jan 4, 2022 21:19 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 400 $7.26 $2,904.00
Disclosure

SEC source: 0001209191-22-000730 · doc4.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
December 01, 2021 Filed Dec 2, 2021 22:43 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 400 $0.00 Strike: $7.26 $0.00
Disclosure

SEC source: 0001209191-21-067685 · doc4.xml · derivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,866

Underlying: Common Stock · 400 shares

Expires 2030-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

Read SEC document
December 01, 2021 Filed Dec 2, 2021 22:43 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 400 $29.13 $11,652.00
Disclosure

SEC source: 0001209191-21-067685 · doc4.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,197

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
December 01, 2021 Filed Dec 2, 2021 22:43 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 400 $7.26 $2,904.00
Disclosure

SEC source: 0001209191-21-067685 · doc4.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
November 01, 2021 Filed Nov 2, 2021 21:28 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 400 $0.00 Strike: $7.26 $0.00
Disclosure

SEC source: 0001209191-21-062466 · doc4.xml · derivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,266

Underlying: Common Stock · 400 shares

Expires 2030-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

Read SEC document
November 01, 2021 Filed Nov 2, 2021 21:28 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 400 $33.24 $13,296.00
Disclosure

SEC source: 0001209191-21-062466 · doc4.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,197

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
November 01, 2021 Filed Nov 2, 2021 21:28 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 400 $7.26 $2,904.00
Disclosure

SEC source: 0001209191-21-062466 · doc4.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
October 27, 2021 Filed Oct 28, 2021 23:23 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 400 $0.00 Strike: $7.26 $0.00
Disclosure

SEC source: 0001209191-21-061973 · doc4.xml · derivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,666

Underlying: Common Stock · 400 shares

Expires 2030-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

Read SEC document
October 27, 2021 Filed Oct 28, 2021 23:23 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 400 $35.00 $14,000.00
Disclosure

SEC source: 0001209191-21-061973 · doc4.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,197

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
October 27, 2021 Filed Oct 28, 2021 23:23 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 400 $7.26 $2,904.00
Disclosure

SEC source: 0001209191-21-061973 · doc4.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
October 01, 2021 Filed Oct 4, 2021 21:16 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 400 $0.00 Strike: $7.26 $0.00
Disclosure

SEC source: 0001209191-21-059064 · doc4.xml · derivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,066

Underlying: Common Stock · 400 shares

Expires 2030-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

Read SEC document
October 01, 2021 Filed Oct 4, 2021 21:16 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 400 $29.92 $11,968.00
Disclosure

SEC source: 0001209191-21-059064 · doc4.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,197

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
October 01, 2021 Filed Oct 4, 2021 21:16 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 400 $7.26 $2,904.00
Disclosure

SEC source: 0001209191-21-059064 · doc4.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
September 07, 2021 Filed Sep 8, 2021 21:08 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 1,600 $0.00 Strike: $7.26 $0.00
Disclosure

SEC source: 0001209191-21-055171 · doc4.xml · derivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,466

Underlying: Common Stock · 1,600 shares

Expires 2030-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

Read SEC document
September 07, 2021 Filed Sep 8, 2021 21:08 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 1,600 $35.00 $56,000.00
Disclosure

SEC source: 0001209191-21-055171 · doc4.xml · nonDerivative · entry 2

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,197

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
September 07, 2021 Filed Sep 8, 2021 21:08 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 1,600 $7.26 $11,616.00
Disclosure

SEC source: 0001209191-21-055171 · doc4.xml · nonDerivative · entry 1

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,797

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
September 01, 2021 Filed Sep 2, 2021 20:22 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 400 $0.00 Strike: $7.26 $0.00
Disclosure

SEC source: 0001209191-21-054434 · doc4.xml · derivative · entry 3

Hansen Gwenn · CIK 0001817160 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,066

Underlying: Common Stock · 400 shares

Expires 2030-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.